Eighty-eight patients with obesity with mild cognitive impairment(MCI) from the Multicenter Nutrition and Chronic Disease Cohort, who met the inclusion and exclusion criteria, were selected as study subjects and randomly divided into 2 groups, i.e., the placebo group and the n-3 PUFA intervention group. Subjects in the intervention group were given supplemental n-3 PUFA (supplied in 1.36 g fish oil capsules); the placebo group took placebo (1.36 g/d), and the intervention period was 12 consecutive months. General information, dietary intake, body composition, exercise, overall cognitive function and multidimensional cognitive function, abundance of Mycobacterium avium and its metabolites acetic acid and propionic acid content, beige adiposity markers, inflammation-related factors, and lipid metabolism were collected at baseline, at the end of 6 months and at the end of 12 months of the intervention, respectively, and the adherence of the two groups of subjects was also assessed. To analyze the effects of n-3 PUFA intervention on cognitive function in patients with obesity with MCI and to explore the possible mechanisms.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Height, Waist
Timeframe: Baseline, 6 months, 12 months
weight
Timeframe: Baseline, 6 months, 12 months
Total Body Water
Timeframe: Baseline, 6 months, 12 months
body protein, inorganic salts, and body fat
Timeframe: Baseline, 6 months, 12 months
Appendicular skeletal muscle mass index
Timeframe: Baseline, 6 months, 12 months
Cognitive function assessment
Timeframe: Baseline, 6 months, 12 months
Dietary composition
Timeframe: Baseline
Dietary Inflammation Index
Timeframe: Baseline
Species and abundance of intestinal flora
Timeframe: Baseline, 6 months, 12 months
Metabolite levels of intestinal flora
Timeframe: Baseline, 6 months, 12 months
Plasma inflammatory factor levels
Timeframe: Baseline, 6 months, 12 months
Erythrocyte Membrane n-3 PUFA Levels
Timeframe: Baseline, 6 months, 12 months
Plasma Beige Lipid Marker Levels
Timeframe: Baseline, 6 months, 12 months
Fecal Akkermansia abundance
Timeframe: Baseline, 6 months, 12 months
Fecal Amuc_1100 expression levels
Timeframe: Baseline, 6 months, 12 months
Detection of signaling pathway related indicators of plasma fat metabolism
Timeframe: Baseline, 6 months, 12 months
Levels of lipopolysaccharide
Timeframe: Baseline, 6 months, 12 months
Plasma lipid oxide concentrations
Timeframe: Baseline, 6 months, 12 months
Levels of fatty acid synthetase
Timeframe: Baseline, 6 months, 12 months